Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases

BACKGROUND: The BNT162b2 mRNA COVID-19 vaccine has been administered to children and adolescents with cancer and hematologic diseases since they are at high risk of manifesting severe symptoms if they have COVID-19 infection but the adequate immune response after vaccination in these immunocompromis...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587837/
https://www.ncbi.nlm.nih.gov/pubmed/35763647
http://dx.doi.org/10.31557/APJCP.2022.23.6.2049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587837/
https://www.ncbi.nlm.nih.gov/pubmed/35763647
http://dx.doi.org/10.31557/APJCP.2022.23.6.2049

Ejemplares similares